GTS Securities’s 10x Genomics TXG Stock Holding History

GTS Securities’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,793	Closed	-$266K	–	1798
2025 Q3	$266K	Buy	+22,793	New	+$297K	0.01%	1119

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTS Securities's TXG Position: Q4 2025 in Review

GTS Securities sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 22,793 shares — an estimated $266K sold.

GTS Securities first reported a position in TXG in Q3 2025 and held it in 1 quarter. The position peaked at $266K in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

GTS Securities reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
GTS Securities sold 22,793 10x Genomics shares in Q4 2025, an estimated $266K.
GTS Securities first reported a position in 10x Genomics in Q3 2025 and held it in 1 quarter.
GTS Securities's 10x Genomics position peaked at $266K in Q3 2025.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on GTS Securities's 13F filing for Q4 2025, filed 13 Feb 2026.